Genentech: FDA Grants Priority Review To Fenebrutinib NDA For Relapsing And Primary Progressive MS

Genentech, a Roche affiliate, said the FDA accepted its New Drug Application for fenebrutinib under priority review. The application covers both relapsing and primary progressive disease indications, signaling an accelerated regulatory timeline for the therapy.